Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

Denali and Sanofi are also developing SAR443122/DNL758 (eclitasertib), a peripheralRIPK1 inhibitor, for the treatment of ulcerative colitis. The cash position is sound as well. Cash, cash equivalents and marketable securities totaled approximately $1.43 billion as of Mar 31, 2024. In February, Denali announced the completion of a private investment in public equity (PIPE) financing with gross proceeds of$500 million. Denali's pipeline potential and the successful development of any of these candidates will ...